Confidentiality Policy: Submitted manuscripts are considered both CONFIDENTIAL and EMBARGOED from the time of submission. In compliance with the Embargo Policy, no information beyond that contained in the Abstract, can be made public before the manuscript has been published. Manuscripts containing a substantial amount of overlapping information that has been previously published or made available to the readership through other venues are ineligible. For more information on BJMBR’s originality requirements and what constitutes prior publication, please scroll down to the Originality section below.

The Confidentiality and Embargo Policies require that, prior to the embargo being lifted, all authors of the research are not allowed to:

Publish the information or provide it to others who may publish or disseminate it through other venues.

Use the information for trading in the securities of any issuer, or provide it to others who may use it for securities trading purposes.

The corresponding author is responsible for conveying this information to all parties.


The Conduct Policy describes the responsibilities of authors, reviewers, and editors, and sets out the Journal of Clinical Oncology’s approach to addressing potential misconduct when concerns arise.

Recusal Guidelines for Editors and Reviewers

BJMBR Editors (including the Editor-in-Chief, Associate Editors, Deputy Editors and Consulting Editors) and Reviewers are required to recuse themselves when the following circumstances arise:

The Editor or Reviewer is the spouse, domestic partner, parent, sibling or child of an author on the manuscript.

The Editor or Reviewer is currently employed by, or has his or her principle practice or research site at, the same institution or organization as an author on the manuscript.

The Editor or Reviewer is involved in ongoing, direct research collaboration with the author, including as a co-investigator or co-author on a different manuscript.

[Note: Membership in the same cooperative group as an author is not grounds for recusal. However, participation as an investigator on the same cooperative group study as an author is grounds for recusal.]

The Editor or Reviewer has a relationship with a commercial interest that is relevant to the subject matter of the manuscript.

The Editor or Reviewer has a relationship, not listed above, that would impact his or her ability to provide a fair and objective review.

Recusal is also required upon request by the BJMBR Editor-in-Chief.

Questions about the recusal process should be directed to BJMBR staff, who will provide advice in consultation with the Editor-in-Chief, as appropriate.


Authors submit manuscripts with the understanding that, if accepted, the copyright of the article, including the right to reproduce the article in all forms and media, shall be assigned exclusively to ASCO.

If any portion (e.g., a figure or table) of a manuscript submitted for consideration has been published previously, authors must acknowledge the original source, and submit written permission from the copyright holder to reproduce the material. Permission is required regardless of authorship or publisher, except for documents in the public domain. To request permission from a copyright holder, authors may find it helpful to use the permission template.

Upon submission, authors are required to upload these permission statements from the copyright holder using the Manuscript Processing System. An accepted manuscript will not be published if the necessary permissions have not been granted.

ASCO will not refuse any reasonable request for permission to reproduce any material published in BJMBR. Authors should e-mail requests to


Manuscripts must contain original material that is not already available elsewhere. However, authors are allowed to submit and present abstracts (i.e., oral or poster presentations) of their research in open, scientific meetings.

The title page and cover letter should include a statement verifying the originality of the work, and disclose any previous abstracts, presentations, reports, or publications that contain material that might be perceived to overlap with the current submission. If a similar publication exists, the authors should upload a copy as a supplemental file as part of the submission process, and justify why their submission is considered non-overlapping and novel. If applicable, authors should cite any previously published or closely related work within the text.

BJMBR will not accept for review any manuscript that is currently under review at another journal.

Authors can post their results in clinical trial registries or submit them to government regulatory agencies (e.g., FDA or EMA) without the manuscript being considered previously published or an overlapping publication.

BJMBR follows the guidelines from the International Committee of Medical Journal Editors section on Overlapping Publications (Overlapping Publications)

On rare occasions, BJMBR will consider co-publication of guidelines manuscripts with a limited number of other journals, assuming that the following conditions are met:

A written request must be approved by the Editor-in-Chief prior to guidelines manuscript submission, justifying the need for co-publication, as well as indicating the specific journals being considered.

BJMBR editors retain responsibility for evaluating the guidelines manuscript and deciding its appropriateness for BJMBR, including peer review, revision, and final decision making.

Should the guidelines manuscript be accepted by BJMBR, transfer of the copyright to ASCO will occur per our usual process. Such a copyright may be shared with the other journals involved.

Online co-publication of the guidelines manuscript must occur simultaneously in all involved journals. The corresponding author of the guidelines manuscript accepts responsibility for ensuring that this will occur.

Conflict of Interest

In compliance with standards established by ASCO’s Conflict of Interest Policy (J Clin Oncol 31:2043, 2013), ASCO’s intent is to promote balance, independence, objectivity, and scientific rigor in all of its editorial policies related to BJMBR, through the disclosure of financial and other interests, and in the identification and management of potential conflicts. The financial interests or relationships requiring disclosure are outlined in the ASCO Conflict of Interest Policy. All contributors to BJMBR are required to disclose financial and other relationships with entities that have an investment, licensing, or other commercial interest in the subject matter of their manuscript. These disclosures should include, but are not limited to, relationships with pharmaceutical and biotechnology companies, device manufacturers, or other commercial entities whose products or services are related to the subject matter of the submission.

Disclosures of financial interests or relationships involving the authors must be addressed on the Author Disclosure Declaration. Each author must complete a declaration form for each manuscript submitted. The corresponding author must enter this information as part of the online submission process, but should not send hard copies of the forms to the Editorial Office.

For new submissions started after 6:30 pm EDT on March 24, 2014, please use the new BJMBR Author Disclosure Declaration and Author Contribution form.

This form is also available for download in the Author Area of the manuscript processing system or upon request from the Editorial Office. The Editorial Office recommends that corresponding authors collect the Author Disclosure Declaration from all other authors before starting the formal online submission. All disclosures appear in print at the end of all published articles.

Please note that authors being solicited for editorials or podcasts should alert BJMBR immediately if there is a conflict of interest that might be perceived to bias their ability to provide objective commentary on a given paper. BJMBR reserves the right to decline an editorial or podcast contribution if there is sufficient evidence to give the appearance of a conflict of interest.

Disclosure of Research Funding Instructions

Disclose financial research support received from commercial entities under question #7 (Research Funding) on the Author Disclosure Declaration (note that funding from government or nonprofit entities should not be disclosed here).

Acknowledge financial research support of the study on the manuscript title page (see Manuscript Preparation Guidelines), rather than on the form.

Disclose commercial research funding received by an author’s institution, cooperative group, or clinical division on the form if the author has received benefit (eg, salary support).

For more information, see Questions and Answers Regarding the ASCO Conflict of Interest Policy.

Editors and Reviewers

Editors and reviewers are required to disclose financial interests or relationships, and are asked to answer the same questions as authors. Reviewers are asked to disclose potential conflicts when accepting a review assignment. These disclosures are held in confidence within the Editorial Office, while the Editors’ disclosures are published online annually as an adjunct to “BJMBR and the Public Trust” (J Clin Oncol 24:323, 2004). To find the Editors’ disclosure information, click on the Editors’ Disclosure Statement link associated with this article.

If in doubt about reporting any potential conflict of interest, it is better to declare a conflict than not. For additional information regarding ASCO’s Conflict of Interest Policy, see this Web site.

Authorship Contributions

BJMBR adheres to the guidelines on authorship established by the International Committee of Medical Journal Editors statement on Authorship and Contribution. According to these guidelines, the criteria established for authorship are intended to present an honest account of what took place. Those with substantial intellectual contributions or who have written the manuscript should be included as an author.

Entering patients for study or providing funding or administrative oversight are not sufficient for authorship; instead these contributions should appear in the Acknowledgment section.

If someone other than the authors, such as a science writer or corporate employee, has participated in writing the paper, this participation must be disclosed. If a multicenter group conducted the research, the group should identify a writing committee that accepts direct responsibility for the manuscript.

Authors themselves, not BJMBR, are responsible for settling any disputes about authorship, acknowledgements, or institutional affiliations. In addition, the authors themselves, not BJMBR, are responsible for ensuring proper attribution of institutions and agencies where the research was conducted.

Author Contribution Forms must be completed and submitted as part of every online submission. These forms should be forwarded to the corresponding author, rather than the Editorial Office.

For new submissions started after 6:30 pm EDT on March 24, 2014, please use the new BJMBR Author Disclosure Declaration and Author Contribution form.

The forms are also available in the Author Area of the manuscript processing system or upon request from the Editorial Office.

Corresponding Author

Selecting the corresponding author:

The corresponding author is the primary contact with the journal.

Any author can be the corresponding author.

Only one author can be the corresponding author.

Role of the corresponding author:

meets submission requirements and submits the manuscript to the journal

ensures all authors have reviewed and approved the final version of the manuscript prior to submission

ensures completion of authorship forms—this includes conflicts of interest forms for all authors

distributes decision letters, reviewer comments, and other messages from the journal, and distributes proofs among coauthors for review

returns corrections and ensures that all authors approve each version of the article